'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
Eris Lifesciences Limited
ERIS (NSE) · ERIS (BSE 540596) · ISIN INE406M01024 · Pharmaceuticals · Est. 2007 · listed 2017 · website
Not on any surveillance list
In Q1 FY27 (quarter to 30 June 2026, standalone), revenue was ₹443.99 cr and profit after tax ₹48.3 cr. Revenue was 23.3% lower than in Q1 FY26.
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q1 FY27 standalone | ₹443.99 cr | ₹48.3 cr | 3.48 | 29 Jul 2026 |
| Q4 FY26 standalone | ₹277.31 cr | −₹8.6 cr | −0.63 | 20 May 2026 |
| Q3 FY26 standalone | ₹315.29 cr | ₹3.09 cr | 0.23 | 13 Feb 2026 |
| Q2 FY26 standalone | ₹650.5 cr | ₹149.57 cr | 10.96 | 12 Nov 2025 |
| Q1 FY26 standalone | ₹578.64 cr | ₹99.99 cr | 7.33 | 5 Aug 2025 |
| Q4 FY25 standalone | ₹404.77 cr | ₹30.47 cr | 2.23 | 19 May 2025 |
| Q3 FY25 standalone | ₹1,292.98 cr | ₹46.92 cr | 3.44 | 5 Feb 2025 |
| Q2 FY25 standalone | ₹877.92 cr | ₹45.14 cr | 3.31 | 25 Oct 2024 |
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹3,195.46 cr | ₹2,075.56 cr | ₹5,777.94 cr |
| 30 Sep 2025 standalone | ₹2,770.57 cr | ₹2,189.22 cr | ₹5,436.92 cr |
| 31 Mar 2025 standalone | ₹2,514.9 cr | ₹2,212.95 cr | ₹5,222.43 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 54.74% | 5.74% | 20.20% | 45.26% |
Latest filings
- Eris Lifesciences Limited has informed the Exchange about Link of Recording 26 October 2026 · NSE
- Eris Lifesciences Limited has informed the Exchange about Investor Presentation 26 October 2026 · NSE
- Eris Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 26 October 2026 · NSE
- Annual Report FY2025-26 (New) 2 September 2026 · NSE
- Eris Lifesciences Limited has informed the Exchange about Transcript 4 August 2026 · NSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Cipla Limited
- Dr. Reddy's Laboratories Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Aurobindo Pharma Limited
- Divi's Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 26 October 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.